Sanofi settles antitrust lawsuit over Lantus insulin pens
Sanofi agreed to settle a long‑running antitrust case alleging it used patent listings to delay generic competition for its Lantus SoloStar insulin pens. The settlement was filed in a Massachusetts federal court, avoiding a trial that had been set for January. Plaintiffs included major distributors Cencora, Cardinal Health and McKesson. Financial terms were not disclosed and Sanofi said the agreement does not admit wrongdoing.
Why it matters
The settlement removes litigation risk for Sanofi, but the lack of disclosed financial terms leaves the impact on the company’s earnings uncertain (the company confirmed the terms will remain confidential).
Key facts
- 1Sanofi filed a settlement agreement in a Massachusetts federal court on Tuesday, ending a case scheduled for a January trial. pymnts.com
- 2The lawsuit was brought by distributors Cencora, Cardinal Health and McKesson, among others. pymnts.com
- 3Sanofi said the settlement does not constitute an admission of wrongdoing. pymnts.com
- 4The settlement amount was not disclosed. news.bloomberglaw.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.